m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study

Robert D. Hilgers; Sewa S. Legha; George A. Johnston; David S. Alberts; Ronald L. Stephens; Bill L. Tranum; Edward V. Hannigan

doi:10.1007/BF00175388

m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study

Robert D. Hilgers, Sewa S. Legha, George A. Johnston, David S. Alberts, Ronald L. Stephens, Bill L. Tranum, Edward V. Hannigan

Cancer Center

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M²/d × 3d q 21 d and four patients were treated at 40 mg/M²/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.

Original language	English (US)
Pages (from-to)	335-338
Number of pages	4
Journal	Investigational New Drugs
Volume	2
Issue number	3
DOIs	https://doi.org/10.1007/BF00175388
State	Published - Sep 1984

Keywords

4′-(9-acridinyl-amino)methanesulfon-m-anisidide
Phase II clinical trial
adenocarcinoma of the endometrium
m-AMSA

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00175388

Fingerprint Dive into the research topics of 'm-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study'. Together they form a unique fingerprint.

Cite this

@article{96215f9f272c4cc58d72e6f8c848d8b4,

title = "m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study",

abstract = "Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.",

keywords = "4′-(9-acridinyl-amino)methanesulfon-m-anisidide, Phase II clinical trial, adenocarcinoma of the endometrium, m-AMSA",

author = "Hilgers, {Robert D.} and Legha, {Sewa S.} and Johnston, {George A.} and Alberts, {David S.} and Stephens, {Ronald L.} and Tranum, {Bill L.} and Hannigan, {Edward V.}",

year = "1984",

month = sep,

doi = "10.1007/BF00175388",

language = "English (US)",

volume = "2",

pages = "335--338",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study

AU - Hilgers, Robert D.

AU - Legha, Sewa S.

AU - Johnston, George A.

AU - Alberts, David S.

AU - Stephens, Ronald L.

AU - Tranum, Bill L.

AU - Hannigan, Edward V.

PY - 1984/9

Y1 - 1984/9

N2 - Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.

AB - Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.

KW - 4′-(9-acridinyl-amino)methanesulfon-m-anisidide

KW - Phase II clinical trial

KW - adenocarcinoma of the endometrium

KW - m-AMSA

UR - http://www.scopus.com/inward/record.url?scp=0021229501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021229501&partnerID=8YFLogxK

U2 - 10.1007/BF00175388

DO - 10.1007/BF00175388

M3 - Article

C2 - 6548984

AN - SCOPUS:0021229501

VL - 2

SP - 335

EP - 338

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -